- Home
- VCNX vs LFLY Comparison
VCNX vs LFLY Comparison
Compare VCNX & LFLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCNX
- LFLY
- Stock Information
- Founded
- VCNX 2001
- LFLY 2010
- Country
- VCNX United States
- LFLY United States
- Employees
- VCNX N/A
- LFLY N/A
- Industry
- VCNX Biotechnology: Pharmaceutical Preparations
- LFLY Computer Software: Prepackaged Software
- Sector
- VCNX Health Care
- LFLY Technology
- Exchange
- VCNX Nasdaq
- LFLY Nasdaq
- Market Cap
- VCNX 4.5M
- LFLY 4.0M
- IPO Year
- VCNX N/A
- LFLY N/A
- Fundamental
- Price
- VCNX $3.22
- LFLY $1.54
- Analyst Decision
- VCNX
- LFLY Strong Buy
- Analyst Count
- VCNX 0
- LFLY 2
- Target Price
- VCNX N/A
- LFLY $7.59
- AVG Volume (30 Days)
- VCNX 167.3K
- LFLY 47.8K
- Earning Date
- VCNX 11-29-2024
- LFLY 11-07-2024
- Dividend Yield
- VCNX N/A
- LFLY N/A
- EPS Growth
- VCNX N/A
- LFLY N/A
- EPS
- VCNX N/A
- LFLY N/A
- Revenue
- VCNX $388,000.00
- LFLY $35,868,000.00
- Revenue This Year
- VCNX N/A
- LFLY N/A
- Revenue Next Year
- VCNX N/A
- LFLY N/A
- P/E Ratio
- VCNX N/A
- LFLY N/A
- Revenue Growth
- VCNX N/A
- LFLY N/A
- 52 Week Low
- VCNX $1.39
- LFLY $1.32
- 52 Week High
- VCNX $13.02
- LFLY $6.49
- Technical
- Relative Strength Index (RSI)
- VCNX 48.87
- LFLY 39.51
- Support Level
- VCNX $2.87
- LFLY $1.32
- Resistance Level
- VCNX $3.43
- LFLY $1.87
- Average True Range (ATR)
- VCNX 0.53
- LFLY 0.19
- MACD
- VCNX 0.05
- LFLY -0.01
- Stochastic Oscillator
- VCNX 23.22
- LFLY 32.74
About VCNX Vaccinex Inc.
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.
About LFLY Leafly Holdings Inc.
Leafly Holdings Inc operates an online cannabis information resource platform. It offers cannabis retailers and brands subscription-based marketplace listings that provide its cannabis audience with information, reviews, menus, and ordering and delivery options through legal retailers.